To establish a serially transplantable PDX model for CMML we used lentiviral expression of MN1 in primary CMML cells for oncogenic supplementation and evaluated the growth potential of these cells in vivo by serial transplantations, a functional in vivo shRNA screen and a novel combination treatment in vivo. The gene discussed is MN1; the disease is chronic myelomonocytic leukemia.